Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by whisky11on Apr 29, 2021 10:31am
132 Views
Post# 33090581

RE:RE:RE:I must say…

RE:RE:RE:I must say…Red~One]The announcement of the Reverse Split has a lot to do with why this stock is struggling when it has such potential

whisky11:  unfortunately  press releases are targeting people  already invested in Claritas.
I know about Sanotize from the media not from company website. As long as there is no massive  sell off we are OK.
Today's volume in dollars is around C$8000 so I don't see people want to sell .

.
Level II Quotes
Orders
Shares
Bid
Ask
Shares
Orders
89
5,029,000
0.04
0.045
1,444,000
16
35
4,746,000
0.035
0.05
3,164,000
47
23
3,911,000
0.03
0.055
2,012,000
38
12
2,133,000
0.025
0.06
1,347,000
20
13
2,948,000
0.02
0.065
1,083,000
18

<< Previous
Bullboard Posts
Next >>